The International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) is to promote public health through international harmonization of technical requirements that contribute to the prevention of unnecessary duplication of non-clinical studies, and to the minimization of the use of animal testing without compromising safety and effectiveness. A major output of ICH’s work is the development by working groups of harmonized technical guidelines and other work products to support harmonization activities on quality, safety, efficacy and multidisciplinary topics. In case of the safety topics, these activities were progressed on 7 topics by technical working groups〔including expert working groups (EWG) and implementation working groups (IWG)〕from May 2017 to June 2019. Namely, Q & A of ICH S3A (the assessment of systemic exposure in toxicity studies focus on microsampling) and Q & A of ICH S9 (Nonclinical Evaluation for Anticancer Pharmaceuticals) were adopted by the regulatory members of the ICH assembly at Step 4 of the ICH process. The EWG of ICH S5 (R3) (Detection of Reproductive and Developmental Toxicity for Human Pharmaceuticals) and ICH S11 (Nonclinical Safety Testing in Support of Development of Paediatric Medicines) address the comments received during the regional public consultation period. ICH S1 (R1) EWG (Rodent Carcinogenicity Studies for Human Pharmaceuticals) continues its work on drafting revision to the guideline. In 2018, ICH S7B IWG (The nonclinical Evaluation of the Potential for delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals) and ICH M7 (R2) EWG/IWG (Assessment and Control of DNA Reactive Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk) were endorsed by the ICH assembly and started to develop each Q & A.